H1 and Q2 2025 results
29 July 2025
AstraZeneca results: H1 and Q2 2025
Strong growth momentum continues with excellent R&D pipeline delivery in the year-to-date
Revenue and EPS summary
| H1 2025 | % Change | Q2 2025 | % Change | |||
| $m | Actual | CER1 | $m | Actual | CER | |
| - Product Sales | 26,670 | 8 | 10 | 13,795 | 11 | 10 |
| - Alliance Revenue | 1,293 | 38 | 38 | 654 | 36 | 35 |
| Product Revenue2 | 27,963 | 9 | 11 | 14,449 | 12 | 11 |
| Collaboration Revenue | 82 | 68 | 66 | 8 | >2x | >2x |
| Total Revenue | 28,045 | 9 | 11 | 14,457 | 12 | 11 |
| Reported EPS ($) | 3.46 | 31 | 32 | 1.58 | 27 | 31 |
| Core3 EPS ($) | 4.66 | 16 | 17 | 2.17 | 10 | 12 |
Key performance elements for H1 2025
(Growth numbers at constant exchange rates)
Total Revenue up 11% to $28,045m, driven by double-digit growth in Oncology and BioPharmaceuticals
Growth in Total Revenue across all major geographic regions
Core Operating profit increased 13%
Core EPS increased 17% to $4.66
12 positive Phase III readouts and 19 approvals in major regions
Interim dividend increased 3% to $1.03 (76.7 pence, 9.81 SEK)
Pascal Soriot, Chief Executive Officer, AstraZeneca, said:
"Our strong momentum in revenue growth continued through the first half of the year and the delivery from our broad and diverse pipeline has been excellent, with 12 positive key Phase III trial readouts including for baxdrostat, gefurulimab, and Tagrisso in just the past few weeks.
As we enter our next phase of growth, we have pledged $50 billion to continue to grow in the US, which includes the largest manufacturing investment in AstraZeneca's history, set for Virginia. This landmark investment reflects not only America's importance but also our confidence in our innovative medicines to transform global health and power AstraZeneca's ambition to deliver $80 billion revenue by 2030."
Please click on the below link or refer the associated PDF document to view the full announcement.
http://www.rns-pdf.londonstockexchange.com/rns/8920S_1-2025-7-28.pdf
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.